
Determining the optimal duration of treatment for infectious diseases in animals is an ongoing challenge. We typically have very little data to guide us, but lots of deeply ingrained habits and dogma about how to do it. The durations used for treatment of many infectious diseases in pets are longer than those used in comparable diseases in humans, and there doesn’t seem to be any good reason or data to justify it, so we are likely overtreating a lot of animals. We’re slowly making progress on changing some of these dogmatic habits through the development of better evidence-based guidelines (e.g. decreasing duration of treatment for bacterial cystitis as per the ISCAID guidelines), but we still have a long way to go.
Due to the lack of hard data, a lot of treatment duration recommendations come from expert opinion. That’s not inherently bad (since you have to start somewhere, and a good, unbiased expert can certainly help), but we should try to aim high whenever possible. Ideally, we rely on the expert opinion only until we can backfill the data gaps to refine the estimated optimal duration, and then adjust the recommendations as needed. Unfortunately, that doesn’t happen very often, for lots of reasons: lack of funding for proper trials, only a small pool of interested infectious disease researchers, and a huge factor is reluctance to change. People often get very comfortable with what they’ve been taught and what they’re already doing, even when it’s not evidence-based. Change is hard.
Lyme disease is a great example of a disease for which we have very little actual data on treatment duration, but lots of opinions. Newly published in the Journal of the American Veterinary Medical Association is a commentary led by Dr. Fiona Emdin about common approaches to treatment of Lyme disease and the need for proper assessment, along with a call for a randomized control trial to assess shorter treatment durations. (Diagnosis and treatment of Lyme nephritis is an even bigger can of worms, but that’s a topic for another post). Unfortunately the commentary is not open access, but here’s the abstract for those who can’t otherwise access it:
Canine Lyme borreliosis is commonly treated with a 28-day course of doxycycline, a regimen based on historical precedent rather than evidence. Most dogs exposed to Borrelia burgdorferi remain clinically normal despite seroconversion; of those that do develop clinical Lyme disease, the most common presentation is acute or recurrent shifting-leg lameness consistent with Lyme arthropathy. This Viewpoint proposes there is clinical equipoise to evaluate shorter durations of 10 days of doxycycline in dogs with uncomplicated Lyme arthropathy and outlines a prospective parallel-group randomized controlled trial to reassess treatment duration. Determining whether a shorter treatment course is clinically effective also has important implications for antimicrobial stewardship by minimizing unnecessary antimicrobial exposure and selection pressures for antimicrobial resistance.
I’ve still got at least one more topic to come in the vaccination scenarios series as well, so stay tuned for that.








